FDC.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Stats
Šios dienos apimtis	46 681.00
Vidutinė apimtis	260 795
Rinkos kapitalizacija	74.36B
EPS	INR0 ( 2024-02-06 )
Kita pelno data	( INR0 ) 2024-05-22
Last Dividend	INR0.800 ( 2020-03-19 )
Next Dividend	INR0 ( N/A )
P/E	25.70
ATR14	INR0.358 (0.08%)

Tūris Koreliacija

Ilgas: 0.09 (neutral)

Trumpas: -0.01 (neutral)

Signal:(43.958) Neutral

FDC Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
KOTAKBANK.NS	0.848
MAXVIL.NS	0.806

10 Labiausiai neigiamai susiję koreliacijos
GANGOTRI.NS	-0.83

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

FDC Limited Koreliacija - Valiuta/Žaliavos

0.83
( strong )

0.72
( moderate )

0.00
( neutral )

0.83
( strong )

0.08
( neutral )

-0.68
( moderate negative )

FDC Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR17.84B
Bruto pelnas:	INR11.28B (63.24 %)
EPS:	INR11.67

FY	2022
Pajamos:	INR17.84B
Bruto pelnas:	INR11.28B (63.24 %)
EPS:	INR11.67

FY	2022
Pajamos:	INR15.26B
Bruto pelnas:	INR9.78B (64.12 %)
EPS:	INR12.82

FY	2021
Pajamos:	INR13.27B
Bruto pelnas:	INR9.00B (67.82 %)
EPS:	INR17.72

Financial Reports:

No articles found.

FDC Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

FDC Limited Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.35 - low (44.58%) | Divividend Growth Potential Score: 4.19 - Potential for dividend initiation, but uncertain (16.16%)

Information

First Dividend	INR0.100	2002-08-19
Last Dividend	INR0.800	2020-03-19
Next Dividend	INR0	N/A
Payout Date	2020-03-26
Next Payout Date	N/A
# dividends	20	--
Total Paid Out	INR24.83	--
Avg. Dividend % Per Year	0.03%	--
Score	1.69	--
Div. Sustainability Score	4.35
Div.Growth Potential Score	4.19
Div. Directional Score	4.27	--

Next Divdend (Est)
(2024-09-06)

INR0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.69

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0.800	0.38%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RVNL.NS	Dividend Knight	2023-09-20	Annually	6	3.08%
LSIL.NS	Dividend Junior	2023-07-17	Annually	3	0.23%
GEOJITFSL.NS	Dividend Knight	2023-06-30	Annually	20	2.79%
ARVIND.NS	Dividend Junior	2023-07-21	Sporadic	20	0.59%
THEMISMED.NS	Dividend Junior	2023-08-31	Sporadic	18	0.39%
ORIENTELEC.NS	Dividend Junior	2023-07-26	Semi-Annually	7	0.41%
IRFC.NS	Dividend Junior	2023-09-15	Annually	4	2.61%
CUB.NS	Dividend Junior	2023-08-11	Annually	23	0.35%
SHRADHA.NS	Dividend Junior	2023-07-06	Sporadic	6	0.99%
MAPMYINDIA.NS	Dividend Junior	2023-08-25	Annually	3	0.13%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.151	1.500	6.98	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.147	1.500	9.48	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	82.77	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	11.30	2.00	6.23	10.00	[0 - 30]
freeCashFlowPerShareTTM	7.82	2.00	6.09	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.657	1.000	2.38	2.38	[0.2 - 0.8]
operatingProfitMarginTTM	0.183	1.000	8.34	8.34	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.35

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	25.67	1.000	7.51	0	[1 - 100]
returnOnEquityTTM	0.147	2.50	9.67	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	7.82	2.00	7.39	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	11.30	2.00	6.23	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.549	1.500	3.01	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0960	1.000	-0.0998	0	[0.1 - 0.5]
Total Score				4.19

FDC Limited

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.